DAWN Stock Forecast & Price Target

Day One Biopharmaceuticals Inc has demonstrated significant financial growth, reporting total revenue of $131.2 million for the year, driven by increased prescription volumes and improved gross-to-net revenue, including $57.2 million from Ojemda net product sales. The company anticipates continued growth as prescribers gain experience with Ojemda and utilize it in earlier treatment lines, which is expected to enhance treatment duration and outcomes. Furthermore, the enrollment progress in clinical trials and a notable increase in patient prescriptions indicate strong market confidence and an expanding footprint in pediatric cancer therapeutics.

Day One Biopharmaceuticals Inc. faces significant financial challenges that contribute to a negative outlook on its stock. The recent classification of its therapy OJEMDA as pediatric-only by the CMS has resulted in a notable reduction in rebate percentages, leading to a revised estimated gross-to-net impact of 12–15%, down from an earlier forecast of 15–18%. Additionally, the company reported considerable net losses of $65.7 million in the fourth quarter and $95.5 million for the full fiscal year 2024, alongside substantial non-cash stock-based compensation expenses, indicating ongoing financial strain.